Hooper Martyn, Hudson Peter, Porter Fiona, McCaddon Andrew
Chairman, The Pernicious Anaemia Society, Bridgend.
Scientific Advisor, COBALZ Limited, Chester.
Br J Nurs. 2014;23(7):376-81. doi: 10.12968/bjon.2014.23.7.376.
Instigating a patient support group for patients with pernicious anaemia (PA) revealed dissatisfaction with its current diagnosis and treatment. The authors investigated the clinical features, patient experience of diagnosis and treatment of PA in the UK.
A total of 889 patients registered with the PA Society support group completed an online survey or postal questionnaire. Outcome measures included clinical features, length of time to diagnosis and patient satisfaction with current treatment
One-third of patients experienced symptoms for up to 1 year before diagnosis; 14% waited more than 10 years for a diagnosis. Neurological features were highly prevalent, the most common being memory loss and poor concentration. Nearly two-thirds of respondents were dissatisfied with current treatment; 10% used a non-licensed form of B12 to supplement their prescribed injections.
The diagnosis and treatment of PA should be subject to a thorough review. This article discusses the patient survey and results and makes recommendations for how the diagnosis and treatment of PA may be evaluated.
为恶性贫血(PA)患者发起患者支持小组后,发现患者对当前的诊断和治疗不满意。作者调查了英国PA患者的临床特征、诊断和治疗的患者体验。
共有889名注册加入PA协会支持小组的患者完成了在线调查或邮寄问卷。结果指标包括临床特征、诊断所需时间以及患者对当前治疗的满意度。
三分之一的患者在诊断前出现症状长达1年;14%的患者等待诊断超过10年。神经学特征非常普遍,最常见的是记忆力减退和注意力不集中。近三分之二的受访者对当前治疗不满意;10%的人使用非许可形式的维生素B12来补充规定的注射治疗。
PA的诊断和治疗应进行全面审查。本文讨论了患者调查及其结果,并就如何评估PA的诊断和治疗提出了建议。